Korea Arlico Pharm Co.,Ltd. (KOSDAQ:260660)

South Korea flag South Korea · Delayed Price · Currency is KRW
3,640.00
-45.00 (-1.22%)
At close: Apr 28, 2026
-14.35%
Market Cap 56.10B
Revenue (ttm) 201.20B
Net Income (ttm) -605.35M
Shares Out 15.33M
EPS (ttm) -40.00
PE Ratio n/a
Forward PE n/a
Dividend 75.00 (2.08%)
Ex-Dividend Date Dec 29, 2025
Volume 33,215
Average Volume 46,392
Open 3,680.00
Previous Close 3,685.00
Day's Range 3,635.00 - 3,685.00
52-Week Range 3,120.00 - 5,760.00
Beta 0.46
RSI 57.43
Earnings Date n/a

About Korea Arlico Pharm

Korea Arlico Pharm Co.,Ltd. engages in the researches and develops, produces, and sells medicines in South Korea. The company provides ETC, OTC, medical device, and other products; and active ingredients. It offers products in the areas of circulatory system, anti-platelet, dementia, muscle relaxants, diabetes, NSAIDS and analgesics, ointment/cream, respiratory system, gastrointestinal, metabolic disease, antihistamines, anti-virus, genitourinary, alopecia, psychoneurotic, CNS, anthelmintics, and hypnotic diseases. Korea Arlico Pharm Co.,Ltd. w... [Read more]

Industry Pharmaceutical Preparations
Founded 1992
Employees 112
Stock Exchange KOSDAQ
Ticker Symbol 260660
Full Company Profile

Financial Performance

In 2025, Korea Arlico Pharm's revenue was 201.20 billion, an increase of 5.65% compared to the previous year's 190.44 billion. Losses were -605.35 million, -88.70% less than in 2024.

Financial Statements

News

There is no news available yet.